Quantcast

Latest Amylin Stories

2011-05-05 15:15:00

SAN DIEGO, May 5, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Bank of America 2011 Healthcare Conference on Thursday, May 12, 2011 at 3:30 p.m. ET / 12:30 p.m. PT in Las Vegas. David Maggs, M.D., vice president, medical research and development at Amylin Pharmaceuticals, will provide a corporate overview. The presentation will be webcast live through the "Investors" section of Amylin's corporate website at www.amylin.com, and a recording will...

2011-04-27 15:15:00

SAN DIEGO, April 27, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Deutsche Bank 36th Annual Healthcare Conference on Wednesday, May 4, 2011 at 12:15 p.m. ET / 9:15 a.m. PT in Boston. Mark Foletta, senior vice president, finance and chief financial officer at Amylin Pharmaceuticals, will provide a corporate overview. The presentation will be webcast live through the "Investors" section of Amylin's corporate website at www.amylin.com, and a...

2011-04-18 06:30:00

SAN DIEGO, April 18, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter ended March 31, 2011. The Company reported total revenue of $152.7 million for the quarter ended March 31, 2011, which includes net product sales of $150.8 million and revenues under collaborative agreements of $1.9 million. Non-GAAP operating loss was $3.2 million for the quarter ended March 31, 2011, compared to $3.8 million for the same period in 2010....

2011-04-11 15:15:00

SAN DIEGO, April 11, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the first quarter of 2011 on Monday, April 18, 2011 at 8:30 a.m. ET/5:30 a.m. PT. Daniel M. Bradbury, Amylin's president and chief executive officer, will lead the call. On the same date pre-market, Amylin will release financial results for the first quarter of 2011. The call will be webcast live through the "Investors" section of Amylin's corporate...

2011-03-16 07:00:00

SAN DIEGO and OSAKA, Japan, March 16, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that they have suspended clinical activities in an ongoing Phase 2 study examining the safety and effectiveness of the investigational combination therapy pramlintide/metreleptin for the treatment of obesity. The clinical study was voluntarily halted to investigate a new antibody-related laboratory finding with...

2011-03-10 07:00:00

SAN DIEGO, INDIANAPOLIS and WALTHAM, Mass., March 10, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes. (Logo: https://photos.prnewswire.com/prnh/20101020/LA85062LOGO-a) (Logo:...

2011-03-09 15:15:00

SAN DIEGO, March 9, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Barclays Capital Global Healthcare Conference on Wednesday, March 16, 2011 at 10:45 a.m. ET / 7:45 a.m. PT in Miami. David Maggs, M.D., vice president, medical research and development at Amylin Pharmaceuticals, will provide a corporate overview. The presentation will be webcast live through the "Investors" section of Amylin's corporate website at www.amylin.com, and a recording...

2011-03-03 07:00:00

SAN DIEGO, INDIANAPOLIS and WALTHAM, Mass., March 3, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced top-line results from DURATION-6, a head-to-head study designed to compare weekly BYDUREON(TM) (exenatide extended-release for injectable suspension), an investigational type 2 diabetes therapy, to daily Victoza® (liraglutide (rDNA origin) injection). Both drugs are...

2011-02-08 15:15:00

SAN DIEGO, Feb. 8, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the ISI Annual Conference in New York on Tuesday, February 15, 2011 at 4:10 p.m. ET / 1:10 p.m. PT. Mark Foletta, senior vice president, finance and chief financial officer at Amylin Pharmaceuticals, will provide a corporate overview. The presentation will be webcast live through the "Investors" section of Amylin's corporate website at www.amylin.com, and the recording will be made...

2011-01-26 15:05:00

SAN DIEGO, Jan. 26, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter and year ended December 31, 2010. The Company reported total revenue of $174.2 million for the quarter ended December 31, 2010, including net product sales of $162.3 million and revenue under collaborative agreements of $11.9 million. Non-GAAP operating income was $22.9 million for the quarter ended December 31, 2010, compared to non-GAAP operating loss of...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related